NCT05508594View on ClinicalTrials.gov

Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

October 5, 2023

Study Completion Date

October 5, 2023

Conditions
Pain
Interventions
DRUG

CT001

Intranasal

DRUG

Placebo

Intranasal

DRUG

Sufentanil

Intranasal

DRUG

Ketamine

Intranasal

Trial Locations (1)

2400

DanTrials, Copenhagen

Sponsors

Lead Sponsor

Cessatech A/S
All Listed Sponsors
lead

Cessatech A/S

INDUSTRY

NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 | Biotech Hunter | Biotech Hunter